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Altered control of T follicular helper (Tfh) cells can lead to generation of autoantibodies and autoimmune manifestations. 
Signaling pathways that selectively limit pathogenic responses without affecting the protective function of Tfh cells are 
unknown. Here we show that the ATP-gated ionotropic P2X7 receptor restricts the expansion of aberrant Tfh cells and 
the generation of self-reactive antibodies in experimental murine lupus, but its activity is dispensable for the expansion 
of antigen-specific Tfh cells during vaccination. P2X7 stimulation promotes caspase-mediated pyroptosis of Tfh cells and 
controls the development of pathogenic ICOS+ IFN-γ–secreting cells. Circulating Tfh cells from patients with systemic 
lupus erythematosus (SLE) but not primary antiphospholipid syndrome (PAPS), a nonlupus systemic autoimmune disease, 
were hyporesponsive to P2X7 stimulation and resistant to P2X7-mediated inhibition of cytokine-driven expansion. These 
data point to the P2X7 receptor as a checkpoint regulator of Tfh cells; thus, restoring P2X7 activity in SLE patients could 
selectively limit the progressive amplification of pathogenic autoantibodies, which deteriorate patients’ conditions.
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Introduction
T follicular helper (Tfh) cells are a specialized subset of effector 
CD4 T cells that play a crucial role in the generation of protective 
antibody responses against pathogens. However, dysfunctional 
Tfh cells can activate autoantibody-producing B cells that cause 
autoimmunity (Yu and Vinuesa, 2010; Craft, 2012; Crotty, 2014). 
Understanding the regulatory mechanisms that ensure the ho-
meostatic control of Tfh cell activation can provide insight for 
manipulating T cell–dependent antibody responses in autoim-
mune conditions. The Tfh cell differentiation program is imple-
mented by up-regulation of inducible T cell costimulator (ICOS) 
that induces the transcription factor Bcl6 (Nurieva et al., 2008; 
Choi et al., 2011). Bcl6 in turn promotes CXCR5 expression and 
migration of the developing Tfh cell to the B cell follicle (Choi et 
al., 2011; Pepper et al., 2011). The concomitant down-regulation 
of CCR7 and P-selectin glycoprotein ligand 1 (PSGL-1) allows the 
T cell to exit the T cell zone and colocalize with B cells. The ICOS–
ICO SL interaction is important in mediating Tfh cell migration to 
the B cell follicle (Xu et al., 2013). Antigen presentation and ICO SL 
expression by B cells are instrumental to the expansion of Tfh 
cells, resulting in germinal center (GC) formation.
ATP is a ubiquitous extracellular messenger that can act also 
as a danger-associated molecular pattern; it activates puriner-
gic receptors in the plasma membrane termed P2 receptors. The 
P2X7 receptor subtype is an ATP-gated nonselective cationic 
channel characterized by dual gating: whereas P2X7 stimulation 
with ATP in the hundred-micromolar range leads to opening of a 
cytolytic pore and cell death, receptor exposure to low concentra-
tions of ATP (e.g., micromolar range) results in small-amplitude 
currents (Khadra et al., 2013). The P2rx7 gene, encoding for P2X7, 
is widely expressed, with the highest levels in cells from nervous 
and immune systems. Tfh cells express high levels of P2X7 in the 
plasma membrane; in the Peyer’s patches (PPs) of the small in-
testine, they are exposed to extracellular concentrations of ATP 
that promote cell death via P2X7. Consequently, Tfh cells with 
deletion of P2rx7 show resistance to extracellular ATP (eATP)–in-
duced pore opening and cell death. The improved helper activity 
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of P2rx7−/− Tfh cells results in enhanced GC reaction, IgA secre-
tion, and binding to commensals (Proietti et al., 2014).
It is not clear whether eATP might influence Tfh cells at in-
flammatory sites, where it is present at high concentrations 
(Wilhelm et al., 2010). We addressed this issue in chronic in-
flammation elicited by pristane injection that causes a lupus-like 
syndrome in mice (Satoh and Reeves, 1994; Reeves et al., 2009). 
We show that lack of P2X7 in Tfh cells significantly worsened the 
disease by enhancing the generation of autoantibodies. Notably, 
circulating Tfh cells from patients with SLE were almost insensi-
tive to P2X7-mediated control. In contrast, Tfh cells from patients 
with primary antiphospholipid syndrome (PAPS) were inhibited 
by P2X7 stimulation, suggesting that impaired P2X7 activity se-
lectively contributes to the immunopathogenesis of SLE.
Results
P2rx7 deletion exacerbates immunopathology in 
experimental murine lupus
Several key features of SLE can be induced in mice by a single 
i.p. injection of the hydrocarbon oil 2,6,10,14-tetramethylpen-
tadecane (commonly known as “pristane”; Satoh and Reeves, 
1994; Reeves et al., 2009), which provokes peritoneal inflamma-
tion, production of antinuclear antibodies (ANAs) and glomer-
ulonephritis. P2rx7−/− mice treated with pristane showed more 
severe splenomegaly (Fig. 1 A). Pristane-induced lupus (PIL) is 
characterized by peritoneal lipogranulomas, ectopic lymphoid 
structures that sustain autoantibody production (Nacionales et 
al., 2009; Weinstein et al., 2013). We observed more widespread 
lipogranulomas and enhanced glomerular damage in P2rx7−/− 
compared with WT mice (Fig. 1 C). Consistent with these findings, 
proteinuria levels (Fig. 1 B) and IgG immunocomplexes as well as 
complement C3 deposits in the glomeruli (Fig. 1 D) were markedly 
increased in mice lacking P2X7. Overall, these results indicate that 
P2rx7 deletion exacerbates pristane-induced immunopathology.
P2rx7 deletion leads to enhanced secretion of self-reactive 
antibodies and abnormal GC reaction
Administration of pristane results in hypergammaglobulinemia 
and production of ANAs, a hallmark of SLE (Satoh and Reeves, 
1994; Reeves et al., 2009). The serum concentrations of IgG, par-
ticularly IgG1 and IgG2B subtypes, were significantly augmented 
in P2rx7−/− with respect to WT mice, whereas IgG2C, IgM, and IgG3 
were comparable in the two groups of animals (Fig. 2 A). Indirect 
immunofluorescence assay with HEp-2 cells revealed predomi-
nant staining patterns classified as “dominant homogenous” and 
“mixed homogeneous/nucleolar” with sera from P2rx7−/− mice, 
suggesting robust generation of autoantibodies directed against 
nuclear components, whereas sera from WT mice preferentially 
showed cytoplasmic and mixed cytoplasmic/nucleolar patterns 
with minimal reactivity (8% of tested sera) to homogeneous/
nuclear antigens (Fig. 2 B). Semiquantitative detection of IgG re-
active to SLE-specific self-antigens showed significant increases 
of self-reactive IgG in sera from pristane-treated P2rx7−/− mice, 
which showed values more similar to those of autoimmune-prone 
Murphy Roths Large/Lymphoproliferative (MRL/lpr) than to WT 
mice (Fig. 2 C).
The generation of self-reactive antibodies might originate 
from dysregulated immune checkpoint function during B cell 
differentiation. Analysis of the splenic B cell compartment at 8 
mo after pristane administration did not reveal differences in 
the distribution of follicular and marginal zone B cells between 
WT and P2rx7−/− mice (Fig. S1 A). Conversely, splenic plasma 
cells (Fig. 2 E) as well as IgG-secreting cells (Fig. 2 D) were more 
abundant in P2rx7−/− mice. Serum autoantibodies can be gen-
erated through both extrafollicular and GC-derived pathways, 
the latter likely promoting somatic hypermutation and IgG af-
finity maturation. The contribution of GC B cells to PIL immu-
nopathogenesis has not been directly explored so far. Splenic 
PNA+Fas+ GC B cells were unaltered in pristane-treated WT mice 
with respect to untreated animals at 8 mo after pristane admin-
istration. However, these cells were significantly increased in 
P2rx7−/− mice (Fig. 3 A), as were the number and size of GCs de-
tected by immunofluorescence staining of spleen cryosections 
(Fig. 3 B). These experiments suggest that protracted GC reaction 
could be responsible for the enrichment of autoreactive IgG in 
P2rx7−/− mice.
P2rx7 deletion favors the generation of pathogenic Tfh and 
kidney-infiltrating T cells in PIL
Pristane administration induced a significant expansion of ef-
fector/memory CD4 cells in P2rx7−/− mice compared with WT 
mice (Fig. S1 B). Among effector T cells, Tfh cells are specialized 
to provide help to B cells and crucially contribute to GC regu-
lation. Aberrant expansion of Tfh cells is a common feature of 
SLE as well as of several spontaneous and induced models of 
murine lupus. Indeed, flow cytometry and immunofluorescence 
confirmed the follicular localization (Fig. 3 B) and expansion of 
Tfh cells expressing ICOS and PD-1 (Fig. 3 C) in pristane-treated 
P2rx7−/− compared with WT mice. Down-regulation of CCR7 and 
high expression of PD-1 define the immunopathogenic Tfh cell 
phenotype in lupus-prone sanroque mice (He et al., 2013). Anal-
ogously, CCR7lo/−PD-1hi Tfh cells were significantly increased in 
the spleen of pristane-treated P2rx7−/− with respect to WT mice 
(Fig.  3  D). ICOS amplification results in spontaneous autoim-
mune manifestations in sanroque mice (Vinuesa et al., 2005) 
and increased IgG production as well as multiorgan inflamma-
tion in autoimmune-prone MRL/lpr mice (Odegard et al., 2008; 
Teichmann et al., 2015). ICOS-expressing CD4 cells promote ne-
phritis in lupus-prone mice (Odegard et al., 2009) and were de-
tected in renal biopsy of patients with lupus nephritis (Hutloff 
et al., 2004; Cohen et al., 2008). In P2rx7−/− mice, kidney-infil-
trating ICOS+ CD4 cells were significantly increased following 
pristane administration (Fig. S2, A and B), likely contributing to 
the severe glomerular damage observed in these mutant mice.
Immunosuppressive T regulatory (T reg) cells limit the ex-
pansion of autoreactive cells and are considered as potential 
therapeutic tools in autoimmune conditions. Their defect might 
contribute to lupus pathogenesis, although a specific role in 
human SLE is debated (Ohl and Tenbrock, 2015). We did not de-
tect differences in T reg cell representation in the spleen between 
pristane-injected WT and P2rx7−/− mice (Fig. S1 C). Moreover, 
we addressed whether T follicular regulatory (Tfr) cells, which 
represent specialized T reg cells controlling GC reaction (Chung 
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et al., 2011; Linterman et al., 2011; Wollenberg et al., 2011), were 
affected in P2rx7−/− mice. However, we did not detect differences 
in Tfh/Tfr or GC B/Tfr cell ratios in the spleen of treated animals 
(Fig. S1 D), suggesting that P2rx7−/− Tfr cells efficiently expanded 
concomitantly to enhanced Tfh and GC B cells expansion. There-
fore, it seems unlikely they might contribute to deregulated GC 
reaction in P2rx7−/− mice.
P2X7 activity limits the expansion of Tfh cells in PIL but not 
during conventional immunization
A peculiarity of P2X7 among the P2 family of ATP-gated ionic 
channels is the low affinity for ATP; therefore relatively high 
concentrations of ATP (μM range) are required for its activa-
tion. Under physiological conditions, eATP is virtually absent 
in tissue interstitia. However, stress, injuries or inflammation 
considerably enhance the concentration of eATP that acts as 
a danger-associated molecular pattern. To address whether 
P2X7-mediated control of Tfh cell expansion was peculiar for 
the inflammatory and immunopathogenic environment elicited 
by pristane administration but not immunization with a con-
ventional antigen, we immunized WT and P2rx7−/− mice with 
NP16-OVA in MF59, a potent ATP-releasing adjuvant (Vono et al., 
2013; Fig. 4 A). In contrast to the enhanced response to pristane, 
we detected an impaired expansion of Tfh cells and OVA-pep-
tide329–337–specific CD4 cells (Fig. 4 B) as well as NP-specific GC 
B cells (Fig. 4 C) in the draining lymph nodes of P2rx7−/− mice 7 
d after immunization. Boost immunization at 14 d and analysis 
after 7 d showed the persistent reduction of antigen-specific B 
Figure 1. Increased lupus nephritis severity in P2rx7−/− mice. (A) Spleen weight of untreated WT (n = 7), P2rx7−/− (n = 6), pristane-treated WT (n = 19), and 
P2rx7−/− (n = 18) mice. (B) Proteinuria score of pristane-treated WT and P2rx7−/− mice. Each dot represents an individual mouse, and horizontal lines represent 
median values. WT untreated (n = 8), P2rx7−/− untreated (n = 8), WT pristane (n = 47), P2rx7−/− pristane (n = 53). (C) Representative pristane-induced glomerular 
injury in periodic-acid-Schiff–stained kidney sections (bar, 50 µm) with proportion of affected glomeruli (left graph) and glomerular injury score (right graph). WT 
pristane (n = 10), P2rx7−/− pristane (n = 15). (D) Confocal microscopy of kidneys stained for IgG (green) and complement C3 (red) to detect glomerular immune 
deposits. Rag1−/− mice were used as negative control for IgG staining (bars, 20 µm). Histograms show means ± SEM for glomerular IgG (top) and C3 depositions 
(bottom) of three independent experiments. Rag1−/− Ctrl (n = 2), WT untreated (n = 3), P2rx7−/− untreated (n = 3), WT pristane (n = 8), P2rx7−/− pristane (n = 10). 
All data are from mice at 33 wk after injection. Two-tailed Mann–Whitney U test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ns, not significant.
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cells in the spleen of mutant animals (Fig. 4 D) concomitant to 
significantly reduced abundance of both high- and low-affinity 
IgG-secreting B cells specific for NP4 and NP41 antigen, respec-
tively (Fig. 4 D). These cells as well as OVA-peptide329–337–spe-
cific CD4 cells were also significantly reduced in P2rx7−/− mice 7 
d after subcutaneous injection of NP16-OVA in PBS at day 95 after 
primary immunization (Fig. 4 E). These results suggest that en-
hanced GC reaction and hyper-IgG observed in pristane-treated 
P2rx7−/− mice are not general features of the adaptive immune 
response triggered in the absence of P2X7 but characterize the 
immunopathogenic response triggered by pristane. Since P2X7 
is important in promoting the proinflammatory activation of 
APCs during antigen priming of adaptive immunity (Wilhelm et 
al., 2010), the defective antigen responsiveness of P2rx7−/− mice 
could be due to impaired APC activation. To rule out an intrinsic 
defect of P2rx7−/− Tfh cells during antigen priming, we trans-
ferred either WT or P2rx7−/− TCR transgenic CD90.2 OT-II CD4 
cells (specific for OVA peptide 323–339) into congenic CD90.1 WT 
mice and repeated the immunization with NP16-OVA in MF59. 
The analysis of primary as well as reactivated memory response 
revealed undistinguishable frequencies of antigen-specific 
CD4 cells in mice adoptively transferred with WT or P2rx7−/− 
OT-II cells (Fig. 5 A). Conversely, the transfer of CD90.2 WT or 
P2rx7−/− naive T CD4 cells into congenic CD90.1 WT animals and 
subsequent injection of pristane (to reproduce the features of ex-
perimental lupus within this adoptive transfer system) recapit-
Figure 2. Increased serum autoantibodies and splenic plasma cells in P2rx7−/− mice. (A) Serum Ig isotype concentrations in untreated (n = 6 for IgM and 
IgA, n = 16 for total IgG, n = 12 for IgG subclasses) and pristane-treated (n = 15 for IgM and IgA, n = 40 for total IgG, n = 15 for IgG subclasses) mice by ELI SA. 
Mean ± SEM are shown. Two-tailed nonparametric Mann–Whitney U test. (B) Representative immunofluorescence of HEp-2 cells and relative distribution of 
ANA IgG staining patterns with sera from pristane-treated WT and P2rx7−/− mice. Bar, 50 µm. The number in the circle indicates the number of analyzed mice. 
Fisher's exact test with χ2. (C) ELI SA (QUA NTA-Lite ANA) for the semiquantitative detection of self-reactive IgG. Each dot represents an individual mouse, and 
horizontal lines represent median values. MRL/lpr sera were used as positive controls. MRL/lpr (n = 5), WT untreated (n = 11), P2rx7−/− untreated (n = 11), WT 
pristane (n = 29), P2rx7−/− pristane (n = 33). Two-tailed Mann–Whitney U test. Distribution of sera from the indicated mice as nonreactive or reactive in the assay 
is shown. (D) Absolute number of IgG-secreting cells by ELI SPOT assay in spleens from the indicated mice. Mean ± SEM of three independent experiments. WT 
untreated (n = 4), P2rx7−/− untreated (n = 4), WT pristane (n = 7), P2rx7−/− pristane (n = 9). (E) Representative contour plots, relative frequency and absolute 
number of splenic plasma cells gated as TCRβ−CD138+CD44+ cells from untreated WT (n = 6) and P2rx7−/− (n = 5) mice and treated WT (n = 17) and P2rx7−/− (n 
= 16) mice. Two-tailed Mann–Whitney U test. Mean ± SEM are shown in bar graphs. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ns, not significant.
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Figure 3. Increased GC reaction and Tfh cells in P2rx7−/− mice. (A) Representative contour plots for PNA and Fas staining on gated CD19+B220+ splenocytes, 
and frequency and absolute number in untreated (n = 12) and treated (n = 37) WT as well as P2rx7−/− mice. (B) Representative images of spleen sections from 
pristane-treated WT and P2rx7−/− mice stained with anti-IgD, -CD4, –GL-7, and –PD-1 antibodies (bar, 100 µm) and inset zooming on GC cells (bar, 50 µm). The 
number of GCs per field at 10-fold magnification in individual mice (n = 5) and GC areas in WT (n = 22) and P2rx7−/− (n = 37) mice are shown in right panels. 
Two-tailed Mann–Whitney U test. Mean ± SEM are shown in bar graphs. (C) Representative contour plots and frequency and absolute number of CXCR5+ICOS+ 
(untreated WT, n = 10; P2rx7−/−, n = 9; treated WT, n = 30; and P2rx7−/−, n = 34 mice) and CXCR5+PD-1+ (untreated WT, n = 9; P2rx7−/−, n = 8; treated WT, n 
= 17; and P2rx7−/−, n = 22 mice) cells within gated TCRβ+CD4+ splenocytes. Bar graphs: mean ± SEM. Two-tailed Mann–Whitney U test. (D) Representative 
contour plots for CCR7 and PD-1 among CXCR5+ CD4 T cells, and frequency of CCR7lo/–PD-1hi CD4 Tfh cells in the spleen of indicated mice. WT untreated (n = 
8), P2rx7−/− untreated (n = 13), WT pristane (n = 10), P2rx7−/− pristane (n = 17). Two-tailed Mann–Whitney U test. Each dot in graphs represents an individual 
mouse, and horizontal lines represent median values. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ns, not significant.
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ulated the significant increase of donor P2rx7−/− compared with 
WT Tfh cells (Fig. 5 B). Notably, Tfh cell expansion significantly 
correlated with GC B cell abundance (Fig. 5 C) in the recipient 
treated hosts. The contrasting data obtained with the two in vivo 
adoptive transfer models, OVA immunization versus pristane ad-
ministration, support the hypothesis that P2X7 plays an exquisite 
role in limiting the expansion of potentially pathogenic Tfh cells 
upon inflammation and chronic exposure to self-antigens, but its 
activity does not influence Tfh cell response within vaccination.
P2X7 intrinsically regulates the aberrant generation of Tfh 
cells and GC-derived autoantibodies
We investigated whether self-reactive IgG induced by pristane 
originated from a GC-dependent or -independent pathway. To 
address this issue, first we analyzed the impact of the treatment 
in Icos−/−P2rx7−/− mice, which are devoid of Tfh cells and cannot 
generate GCs (Proietti et al., 2014). As expected, in the absence of 
ICOS-dependent generation of Tfh cells we did not detect varia-
tions in GC B cell abundance with respect to untreated animals 
(Fig. 6 A). Consistent with a pathogenic role of ICOS+ Tfh cells in 
PIL, Icos−/−P2rx7−/− mice showed significantly reduced self-reac-
tive IgG in serum (Fig. 6 B) and proteinuria (Fig. 6 C) compared 
with single mutant P2rx7−/− mice. Hence, in the absence of Tfh 
cells and GCs, P2rx7 deletion in B cells does not apparently in-
fluence the generation of pathogenic self-reactive IgG levels as 
observed in P2rx7−/− mice. These data suggest that the proportion 
of extrafollicular self-reactive IgG accounts only for a minority of 
the repertoire of autoreactive antibodies generated by pristane 
injection and that the vast majority of self-reactive IgG detected 
in the sera from pristane-treated P2rx7−/− mice originate from 
GCs and depend on the presence of P2X7-deficient Tfh cells.
To definitely restrict the function of P2X7 in T cells in limit-
ing the generation of immunopathogenic IgG in a GC-competent 
host, we repeated PIL in mice with conditional deletion of P2rx7 
in T cells (Cd4-Cre P2rx7fl/fl). Analogously to P2rx7−/−, Cd4-Cre 
P2rx7fl/fl mice showed increased Tfh and GC B cells in PPs con-
sistent with impaired regulation of Tfh cells by intestinal ATP 
(Proietti et al., 2014). When compared with Cd4-Cre P2rx7WT/WT, 
these mice recapitulated increased splenomegaly and protein-
uria following pristane administration, as previously observed 
in P2rx7−/− versus WT mice (Fig. 1, A and B; and Fig. 7, A and B), 
suggesting these two phenotypic traits of PIL are influenced by 
P2X7 in T cells. Aging (33-wk-old) Cd4-Cre P2rx7fl/fl mice showed 
reduced IgG-secreting cells (Fig. 7 E) and GC B cells (Fig. 7 F) in 
the spleen compared with Cd4-Cre P2rx7WT/WT mice. Moreover, 
serum IgG concentration did not increase upon pristane admin-
istration, as observed in P2rx7−/− mice (Fig. 7 C). It is possible 
that this feature of PIL is not T cell intrinsic but depends on the 
lack of P2X7 in other cells. Moreover, we cannot definitely ex-
clude that the deregulation of other T cell subsets by lack of P2X7 
activity might contribute to the phenotype of pristane-treated 
Cd4-Cre P2rx7fl/fl mice. Nonetheless, the significant worsen-
ing of selected immunopathological features of SLE, including 
ANA serum concentration (Fig. 7 D) and IFN-γ–secreting ICOS+ 
PSGL-1lo/− CD4 cells (Fig. 7 H; see below) in Cd4-Cre P2rx7fl/fl mice, 
together with the observed phenotype of Icos−/−P2rx7−/− animals 
following pristane administration, suggests that P2X7 activity is 
crucial in restraining the T cell helper function to B cells bearing 
self-reactive IgG.
Augmented IFN-γ secretion by PSGL-1lo/− committed Tfh cells 
in pristane-treated P2rx7−/− mice
The lineage-defining transcription factor Bcl6 orchestrates Tfh 
cell differentiation and function via complex and only partially 
understood mechanisms (Hatzi et al., 2015). Bcl6-dependent 
down-regulation of PSGL-1 is part of the Tfh cell differentia-
tion program (Poholek et al., 2010). In MRL/lpr mice, ICOS-de-
pendent interaction with B cells was shown to promote PSGL-1 
down-regulation and autoantibody production (Odegard et al., 
2008). Analogously to these mice, we found a significant increase 
of PSGL-1lo/− cells in pristane-treated P2rx7−/− mice (Fig. 6 D). 
Concomitant Icos deletion abolished PSGL-1 down-regulation 
(Fig. 6 D), suggesting that ICOS-dependent and protracted func-
tional activity in P2rx7−/− cells is responsible for the generation of 
PSGL-1lo/− committed Tfh cells. Expression of IL-21 is considered 
a key feature of normal (Nurieva et al., 2008) as well as patho-
genic Tfh cells (McGuire et al., 2011; Yang et al., 2013; Kim et al., 
2015). However, other proinflammatory cytokines such as IFN-γ 
(Lee et al., 2012; Domeier et al., 2016; Jackson et al., 2016) or IL-17 
(Ding et al., 2013) were implicated in aberrant Tfh cell function. 
Intracellular staining for IL-21, IL-17, and IFN-γ showed a pref-
erential increase in the percentage of IFN-γ–secreting CD4 cells 
in pristane-treated P2rx7−/− mice (Fig. 6 E) that was abolished 
by Icos deletion (Fig. 7 J). Accordingly, we observed a selective 
enrichment of IFN-γ–secreting cells in ICOS+ and PSGL-1lo/− CD4 
cells (Fig. 7 I). As mentioned above, an analogous enrichment was 
also observed in mice with conditional deletion of P2rx7 in CD4 
cells (Fig. 7 H). According to previous data showing the relative 
resistance of P2rx7−/− CD4+ T cells to differentiate along the Th17 
pathway (Schenk et al., 2011), we detected decreased percentages 
of IL-17–secreting cells in pristane-treated P2rx7−/− mice as well 
as decreased percentages of IL-21–secreting cells with respect to 
WT mice (Fig. 7 J). These observations are consistent with the re-
ported role of IFN-γ–secreting Tfh cells in contributing to lupus 
pathology (Lee et al., 2012).
P2X7-mediated pyroptosis of Tfh cells via caspase-mediated 
activation of gasdermin D
Online monitoring of cell permeability to YO-PRO-1 by flow cy-
tometry upon stimulation with the P2X7 agonist 3′-O-(4-benzoyl)
benzoyl ATP (BzATP) is used to assess cellular sensitivity to death 
mediated by cytolytic pore opening. Tfh cells from spleen of pris-
tane-treated WT but not P2rx7−/− mice were sensitive to P2X7 
stimulation in this assay (Fig. 8 A). In T cells, P2X7-mediated pore 
opening and cell death was associated with features characteris-
tic of pyroptosis (Taylor et al., 2008), a form of death executed by 
gasdermin D (Gsdmd) upon caspase-mediated cleavage and relief 
of autoinhibition of the pore forming N terminus (Kayagaki et 
al., 2015; Shi et al., 2015). A search of gene expression profiles in 
public datasets revealed Gsdmd as the most widely represented 
member among the gasdermin family in CD4 naive and Tfh cells 
(Fig. S3 A). In addition, the analysis of caspase expression in 
CD4 naive versus Tfh cells revealed the selective up-regulation 
of caspase-1 and -4 in Tfh cells (Fig. S3 B). Since Gsdmd is a sub-
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Figure 4. Impaired primary, secondary, and memory responses to NP-OVA in P2rx7−/− mice. (A) Scheme of the immunization protocol and time points 
of analysis. (B) Frequency and absolute number of CXCR5+ICOS+ Tfh cells in the draining lymph nodes from untreated or immunized WT and P2rx7−/− mice at 
1 wk after s.c. injection of NP-OVA in MF59 (WT unimmunized, n = 5; P2rx7−/− unimmunized, n = 5; WT NP-OVA, n = 8; P2rx7−/− NP-OVA, n = 8), representative 
contour plots of staining with human CLIP and OVA tetramers, and statistics of OVA tetramer positive cells (n = 4). (C) Frequency and absolute number of GC 
B cells (same samples as above) gated as PNAhiB220+ among CD19+ B cells (upper bar graphs) and of NP-positive GC B cells (lower bar graphs) with represen-
tative contour plots. (D) Frequency and absolute number of NP-positive GC B cells in the spleen of the indicated mice within secondary response to NP-OVA. 
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strate of caspase-1 and -4, this observation suggests that Tfh cells 
could be sensitive to Gsdmd pore-forming activity and execute 
pyroptosis in Tfh cells upon exposure to BzATP. Accordingly, 
BzATP stimulation of Tfh cells isolated from pristane-treated 
WT but not P2rx7−/− mice resulted in caspase activation (Fig. 8 B) 
and generation of cleaved Gsdmd (Fig. 8 C), suggesting that P2X7 
limits Tfh cell survival in eATP-rich microenvironment via Gsd-
md-mediated pyroptotic cell death.
Phenotypic and functional distinction of circulating Tfh cells in 
SLE and PAPS donors
As previously shown (He et al., 2013), we observed significantly 
increased frequencies of the CCR7lo/−PD-1hi subset of circulat-
ing Tfh (cTfh) cells in our cohort of SLE patients (Table S1 and 
Fig.  9  A). Interestingly, the analysis of these cells in patients 
suffering from PAPS did not reveal differences with respect 
to healthy donors (HDs; Fig. 9 A). Moreover, quantification of 
CXCL13 in the blood as a Tfh cells derived biomarker of GC ac-
tivity in humans (Havenar-Daughton et al., 2016) showed the 
significant increase in SLE but not PAPS with respect to HDs 
(Fig. 9 B). These results support a role for deregulated Tfh cells 
in autoantibody generation and pathogenesis in SLE, but not 
PAPS (where SLE features are not observed even in the presence 
of antiphospholipid antibodies, including lupus anticoagulant, 
anti-cardiolipin, or anti-β2-glycoprotein-I antibodies; Ruiz-
Irastorza et al., 2010). To investigate possible differences in cTfh 
cell function in SLE and PAPS, we used a chemokine receptor 
signature, which classifies these cells into three majors subsets: 
efficient B cell helper cells, defined as cTfh2 (CXCR3−CCR6−) and 
cTfh17 (CXCR3−CCR6+) cells, which are increased in some auto-
immune disorders, including SLE, and nonefficient B cell helper 
cTfh1 (CXCR3+CCR6−) cells (Ueno et al., 2015; Blanco et al., 2016). 
We confirmed a significant increase in cTfh2 and a concom-
itant decrease in cTfh1 cells in SLE patients. In contrast, PAPS 
patients were characterized by the increase in a cTfh1/Tfh17 
“hybrid” subset that was negatively associated with disease ac-
tivity in SLE (Choi et al., 2015; Fig. S4 A). SLE and PAPS patients 
showed an opposite trend of the ratio between the sum of cTfh2 
and cTfh17 cells with cTfh1 cells compared with HDs. Whereas 
SLE patients showed a significant increase of this value, as pre-
viously described (Le Coz et al., 2013), PAPS patients displayed a 
significant reduction, thereby defining a functional distinction 
of cTfh cells in these two autoantibody-mediated pathological 
conditions (Fig. S4 B).
Impaired P2X7 receptor activity unleashes Tfh cell 
expansion in SLE
To address possible differences in sensitivity to eATP via P2X7 in 
cTfh cells from SLE versus PAPS, we tested YO-PRO-1 permeabil-
ity in flow cytometry upon stimulation with BzATP. This assay 
is sensitive in detecting P2X7 activity in human cTfh cells, and 
preincubation with the P2X7 inhibitor A438079 completely abol-
ished the dye uptake (Fig. S4 C). These experiments revealed the 
significant reduction of BzATP-sensitive cTfh cells and impair-
ment of YO-PRO-1 permeability in SLE patients with respect to 
both healthy and PAPS subjects (Fig. 9 C). YO-PRO-1 permeability 
by P2X7 stimulation inversely correlated with the frequency of 
CCR7lo/−PD-1hi cTfh cells (Fig. 9 D). Principal component analysis 
(PCA) for the frequencies of CCR7lo/−PD-1hi and YO-PRO-1+ cells 
as well as YO-PRO-1 uptake at 450 s identified two main clusters: 
while HDs and PAPS segregated close to each other, SLE samples 
were clearly differentiated along the first component (Fig. 9 E). 
These results indicate that impaired P2X7 activity might be re-
sponsible for the increase in cTfh cells in SLE. In line with the 
reduced sensitivity to pore formation, P2RX7 mRNA was signifi-
cantly reduced in cTfh cells from SLE with respect to both healthy 
and PAPS donors, suggesting that P2RX7 is selectively down-reg-
ulated in SLE (Fig. 10 B). Stimulation of sorted CD4 naive T cells 
and cTfh cells from HDs with anti-CD3/CD28 antibodies induced 
progressive up-regulation of P2RX7 transcripts, which were 
significantly higher in ex vivo sorted and in vitro activated cTfh 
compared with naive T cells (Fig.  10 A). This up-regulation is 
maintained also by shifting cells in medium with IL-2 after 48-h 
TCR stimulation (Fig. 10 A). The propensity of effector/memory 
CD4 cells to expand in an antigen-independent fashion can be 
scored in vitro by the analysis of cell proliferation in response to 
cytokines (Geginat et al., 2001). Upon stimulation with IL-7 and 
IL-15, CXCR5+ circulating T cells from SLE patients proliferated 
more robustly than cells isolated from healthy or PAPS subjects 
and were significantly more resistant to inhibition of prolifer-
ation by BzATP (Fig. 10 C). Analogous defective inhibition was 
observed also in purified CCR7lo/−PD-1hi cells (Fig. 10 D).
It was recently shown that CD4 naive T cells can differentiate 
into Tfh cells and expand in vitro upon exposure to activin A and 
IL-12 (Locci et al., 2016). The generation and expansion of Tfh 
cells in this assay was significantly inhibited by the addition of 
BzATP (Fig. 10 E). However, CD4 cells from SLE donors generated 
Tfh cells with the same efficiency irrespective of the presence of 
BzATP, suggesting that Tfh cells in SLE are poised to be defective 
in sensing eATP as an inflammatory cue that should limit their 
function (Fig. 10 E). Altogether, these results point to a role for 
P2X7 as a checkpoint regulator for Tfh cells that appears to be 
compromised in SLE.
Discussion
The identification of the sanroque mutation (that disrupts a 
repressor of ICOS) in mice unraveled the causal role of deregu-
lated Tfh cells and GCs in developing high titers of autoantibodies 
and lupus pathology (Vinuesa et al., 2005). We hypothesize that 
WT unimmunized (n = 2), P2rx7−/− unimmunized (n = 2), WT NP-OVA (n = 4), and P2rx7−/− NP-OVA (n = 4). Absolute number of NP-specific IgG secreting cells 
in the spleen (WT NP-OVA, n = 8; and P2rx7−/− NP-OVA, n = 9) and BM (WT NP-OVA, n = 7; and P2rx7−/− NP-OVA, n = 8) of immunized mice. (E) Frequency 
of OVA tetramer positive cells among CD4+ T cells (n = 5) and absolute number of NP-specific IgG secreting cells in the spleen of the indicated mice. WT and 
P2rx7−/− no recall (n = 4), WT and P2rx7−/− NP-OVA (n = 5). Unpaired Student’s t test. Each dot in graphs represents an individual mouse, and horizontal lines 
represent median values. *, P < 0.05; **, P < 0.01. ns, not significant.
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Figure 5. Selective expansion of P2rx7−/− Tfh cells upon pristane injection but not conventional immunization. (A) Scheme of the adoptive transfer and 
immunization experiment; representative plots of donor CD4+ and CXCR5+ICOS+ T cells within transgenic cells recovered from the draining lymph nodes of 
recipient mice 1 wk after primary immunization and frequency of recovered donor cells within individual mice after primary immunization (10 mice per group) 
and secondary response (five mice per group; mean ± SEM). (B) Scheme of the adoptive transfer and pristane administration experiment; representative plots 
of CD90.2+ donor CD4+ T cells from spleen at 2 mo after transfer, frequency of recovered donor CXCR5+ICOS+ CD4+ T cells within individual mice at 1, 2, and 
4 mo after injection of pristane (mean ± SEM). Each dot in graphs represents an individual mouse. Two-tailed Mann–Whitney U test. *, P < 0.05; **, P < 0.01. 
(C) Correlation between GC B cells and donor Tfh cell frequencies at the indicated time points. The correlation coefficient r and the respective P value were 
calculated with nonparametric Spearman test. Each dot in graphs represents an individual mouse.
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P2X7-mediated regulation of Tfh cells can limit potentially patho-
genic GC activity. The abundance of CCR7lo/−PD-1hi cTfh cells in 
the blood correlates with active Tfh cell differentiation (He et 
al., 2013). These cells were selectively enriched and resistant to 
P2X7-mediated cell death in SLE but not PAPS patients. Excessive 
IFN-γ promotes Tfh cell accumulation and lupus-associated pa-
thology (Lee et al., 2012). Our results indicate that P2X7 activity 
might contribute to inhibition of IFN-γ secretion and offset the 
Figure 6. P2X7-mediated control of PSGL-1 down-regulation and IFN-γ secretion in pristane-treated mice. (A) Frequency of PNA+Fas+ GC splenic B 
cells (untreated WT, n = 3; P2rx7−/−, n = 3; and Icos−/−P2rx7−/−, n = 3; pristane-treated WT, n = 9; P2rx7−/−, n = 9; and Icos−/−P2rx7−/−, n = 5). (B) Serum ANA IgG 
detection by ELI SA (MRL/lpr, n = 2; untreated WT, n = 4; P2rx7−/−, n = 4; and Icos−/−P2rx7−/−, n = 5; pristane-treated WT, n = 9; P2rx7−/−, n = 10; and Icos−/−
P2rx7−/−, n = 10). (C) Proteinuria score (untreated WT, n = 3; P2rx7−/−, n = 3; and Icos−/−P2rx7−/−, n = 4; pristane-treated WT, n = 8; P2rx7−/−, n = 8; and Icos−/−
P2rx7−/−, n = 8) in the indicated mice at 33 wk after pristane injection. Each dot represents an individual mouse, and horizontal lines represent median values. 
(D) Representative contour plots for PSGL-1 and CD62L on splenic CD4+ T cells, frequency and absolute number (mean ± SEM) of PSGL1lo/−CD62L− cells from 
untreated WT (n = 12), P2rx7−/− (n = 10), Icos−/−P2rx7−/− (n = 5), treated WT (n = 38), P2rx7−/− (n = 37), and Icos−/−P2rx7−/− (n = 8) mice. (E) Contour plots show 
representative intracellular staining for IL-21, IL-17, and IFN-γ on gated CD4+ICOS+PSGL1lo/− cells from spleens of treated WT and P2rx7−/− mice. Statistics from 
three independent experiments are shown (mean ± SEM, untreated mice, n ≥ 4; treated mice, n ≥ 8). Two-tailed Mann–Whitney U test. *, P < 0.05; **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001. ns, not significant.
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Figure 7. Increased PIL severity and IFN-γ secretion by ICOS+PSGL-1lo/− CD4 T cells in mice with conditional deletion of P2rx7 in T cells. (A) Spleen 
weight of untreated CD4-Cre P2rx7WT/WT (n = 5), CD4-Cre P2rx7fl/fl (n = 12), pristane-treated CD4-Cre P2rx7WT/WT (n = 21), and CD4-Cre P2rx7fl/fl (n = 15) mice. 
(B) Proteinuria score. (C) Serum IgG concentration. (D) Semiquantitative detection of self-reactive IgG by ELI SA (QUA NTA-Lite ANA) in the same mice. (E–G) 
Absolute numbers of IgG-secreting cells (E) and frequencies and absolute numbers of CD19+B220+PNA+ Fas+ (F) and TCRβ+CD4+CXCR5+ICOS+ (G) cells in the 
spleen of the same mice. (H) Representative contour plots for ICOS and PSGL-1 staining among CD4+ T cells from spleen and frequency of IFN-γ secreting 
cells within the ICOS+PSGL-1lo/− CD4+ T cells of the same mice. Each dot represents an individual mouse; median or mean ± SEM is shown. Two-tailed Mann–
Whitney U test. (I) Representative contour plots for ICOS and PSGL-1 staining among CD4+ T cells from the spleen of pristane-treated WT and P2rx7−/− mice, 
Faliti et al. 
P2X7 in limiting pathogenic Tfh cell generation
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20171976
12
risk of GC-driven autoimmunity by chronic Tfh cell stimulation. 
Notably, IFN-γ deficiency did not impair Tfh cell response against 
immunization with foreign antigen (Lee et al., 2012). According 
to a dichotomy of P2X7 in regulating Tfh cell function in acute 
stimulation by cognate antigen versus chronic exposure to in-
flammatory environments, immunization with OVA did not re-
sult in any difference in the expansion of OT-II Tfh cells both in 
primary and secondary response. Whereas P2X7 activity does not 
affect Tfh cell response to “physiological” stimulation by exoge-
nous antigens, it appears to limit immunopathological responses. 
Therefore, restoring P2X7 competence in Tfh cells might improve 
immunopathology in systemic autoimmunity.
The progressive nature of SLE is characterized by the accu-
mulation of new types of autoantibodies up to the clinical onset 
of the disease. Moreover, the appearance of specific autoan-
tibodies, namely anti-Sm and anti–nuclear ribonucleoprotein 
antibodies, tends to coincide with the clinical manifestations of 
SLE. These observations led to the modeling of disease evolution 
into three distinct phases of benign autoimmunity, pathogenic 
autoimmunity, and clinical illness (Arbuckle et al., 2003). The 
genetic as well as environmental factors influencing the develop-
ment of pathogenic autoimmunity in SLE are not defined. SLE is 
a polygenic disease; strong candidates that may cause the disease 
seem to be located across chromosomal bands 12q24.1 to 12q24.3 
(Nath et al., 2004). Together with other potential candidate genes 
in SLE pathogenesis, P2RX7 is located within this chromosomal 
region. Human P2RX7 is highly polymorphic and contains a 
large set of single nucleotide polymorphisms that affect P2X7 
activity. Haplotypes containing the Ala348>Thr polymorphism 
(rs1718119) are characterized by a gain-of-function effect (Stokes 
et al., 2010). Interestingly, this polymorphism was associated 
with lower risk of SLE in a Chinese population (Chen et al., 2013). 
CD4 cells from patients with SLE, but not rheumatoid arthritis, 
exhibited diminished P2X7-dependent ATP-mediated cell death 
compared with healthy controls (Portales-Cervantes et al., 2010). 
We have shown a diminished sensitivity of Tfh cells from SLE but 
not PAPS patients to cytolytic pore opening by P2X7 pharmaco-
logical agonist, suggesting that down-regulation of P2X7 might 
contribute to a selective Tfh cell dysfunction associated with 
SLE. Notably, aging Fas-deficient MRL/lpr mice, which develop 
a lupus-like syndrome, show a drastically reduced sensitivity 
to ATP-mediated stimulation of P2X7 in T cells associated with 
progressive lymphoproliferation (Le Gall et al., 2012). Although 
we cannot exclude that other mechanisms contribute to the im-
paired response of Tfh cells to P2X7 stimulation in SLE patients, 
the observed reduction of P2RX7 mRNA constitutes a possible 
cause. This reduction might be correlated to the pronounced 
changes in microRNAs that characterize SLE and affect lym-
phocyte function and Ig responses (Zan et al., 2014). In innate 
immune system, P2X7 has a well-established role as a trigger for 
inflammatory cytokines release, a feature that fostered the de-
velopment of P2X7 inhibitors to be used as therapeutic drugs in 
autoimmune diseases (Ferrari et al., 2006). Our results suggest 
that P2X7 inhibition in chronic inflammatory conditions where 
GC activity is enhanced might promote the inappropriate expan-
sion of potentially pathogenic Tfh cells.
Materials and methods
Mice
C57/BL6J, P2rx7−/− (B6.129P2-P2rx7tm1Gab/J), Icos−/− (B6.129P2- 
Icostm1Mak/J), OT-II (B6.Cg-Tg(TcraTcrb)425Cbn/J), CD45.1 
(B6.SJL-Ptprca Pepcb/BoyJ), CD90.1 (B6.PL-Thy1a/CyJ), and Cd4-
cre (B6.Cg-Tg(Cd4-cre)1Cwi/BfluJ) mice were from The Jackson 
Laboratory. The P2rx7fl/fl mice were from the European Mouse 
Mutant Archive (EMMA ID 05116; Skarnes et al., 2011). Cd4-Cre 
P2rx7fl/fl mice were generated by crossing the two strains. All 
mice were bred in the specific pathogen–free facility at the Insti-
tute for Research in Biomedicine (IRB), Bellinzona, Switzerland. 
All animal experiments were performed in accordance with the 
Swiss Federal Veterinary Office guidelines and authorized by the 
Cantonal Veterinary.
PIL
SLE was induced by a single i.p. injection of 0.5 ml pristane to 
8-wk-old WT or P2rx7−/− female mice. Mice were monitored 
for clinical signs of SLE until the end of the study (33 wk after 
dosing) and examined for lesions consistent with SLE by kidney 
histology and immunofluorescence, presence of serum autoanti-
bodies by ELI SA, and cell subsets composition by flow cytometry. 
Proteinuria was measured using Bayer Albustix reagent strips on 
collected fresh spots of urine from each mouse. Score from 0 to 4 
was applied as follows: 0, none; 1, trace; 2, 30 mg/ml; 3, 100 mg/
ml; and 4, ≥500 mg/ml.
Immunization and adoptive transfer of CD4 cells
8-wk-old female mice were s.c. injected with 50 µg of NP16-OVA 
(BIO SEA RCH Technologies) in MF59 (AddaVax; InvivoGen). 
Draining lymph nodes and spleen were collected 1 wk after injec-
tion, and cells were analyzed by flow cytometry. For the analysis 
of secondary response, the same immunogen was administered at 
day 14 after primary immunization and cells were analyzed after 
1 wk. For analysis at 102 d after primary immunization, 50 µg of 
NP16-OVA in PBS was administered s.c.; OVA-peptide329–337–spe-
cific CD4 and NP-specific IgG-secreting spleen cells were quan-
tified 1 wk later. For adoptive transfer of OT-II cells, CD4+ cells 
were enriched with anti-CD4 coated magnetic beads (Miltenyi 
Biotec) and sorted as CD4+CD8−CD25−CD44−CD62L+ naive cells on 
a FAC SAria. 8-wk-old CD90.1 mice were injected intravenously 
with 2.5 × 105 sorted cells containing at least 90% OT-II+ cells. 
Recipient mice were immunized 24 h later with a subcutaneous 
injection of 50 µg of NP16-OVA (BIO SEA RCH Technologies) 1:1 in 
and frequency of IFN-γ–secreting cells within the indicated subsets of untreated and treated mice. Statistics from three independent experiments are shown. 
Mean ± SEM (untreated mice, n ≥ 4; treated mice, n ≥ 8). (J) Representative contour plots for intracellular staining of IL-21, IL-17, and IFN-γ in CD4+ T cells from 
spleen of pristane-treated WT, P2rx7−/−, and Icos−/−P2rx7−/− mice and statistics of frequencies. Mean ± SEM (n = 2 independent experiments with at least five 
mice). Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ns, not significant.
Faliti et al. 
P2X7 in limiting pathogenic Tfh cell generation
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20171976
13
MF59 (AddaVax; InvivoGen). For retransfer of activated OT II ef-
fector cells, CD4-enriched cells were sorted for CD90.2 cells, and 
5 × 104 cells were injected intravenously into naive CD90.1 hosts. 
To reactivate memory OT-II cells, recipient mice received a sub-
cutaneous injection of 50 µg of NP16-OVA in MF59 28 d after sec-
ondary transfer, and draining lymph nodes were analyzed 1 wk 
later. For adoptive transfer of polyclonal CD4+ T cells from either 
WT or P2rx7−/− mice, spleens were collected, and CD4+ cells were 
enriched with anti-CD4 coated magnetic beads (Miltenyi Biotec) 
and then sorted as CD4+CD8−CD19−B220−CD11c−CD11b− cells on a 
FAC SAria. 3.5 × 106 cells were injected into CD90.1 WT mice, and 
24 h later, mice were injected i.p. with 0.5 ml pristane. Spleens 
were collected and analyzed 1, 2, or 4 mo after injection.
Histochemistry and immunohistochemistry
All animals were euthanized with CO2, followed by exsanguina-
tion. For histological evaluation, the kidneys were removed, fixed 
in 10% neutral buffered formalin for 48 h, trimmed, dehydrated, 
Figure 8. P2X7-mediated caspase activation and Gsdmd cleavage in Tfh cells. (A) Time monitoring of YO-PRO-1 uptake after stimulation with BzATP in 
ICOS−PD-1− and ICOS+PD-1+ cells within CXCR5+ CD4+ T cells from spleen of WT and P2rx7−/− mice at 33 wk after pristane administration and frequency of 
responding cells in the two subsets from WT mice (n = 14). (B) Analysis by flow cytometry and statistics of caspase activation in purified WT and P2rx7−/− Tfh 
cells upon stimulation with BzATP as indicated (n = 4). (C) Representative Western blot of full-length and caspase-cleaved Gsdmd (FL and Nterm, respectively), 
and actin on the same cells as in B, either untreated or stimulated with BzATP. A shorter exposure for GsdmFL is shown. Histograms show the statistics of 
GsdmdNterm relative expression normalized on GsdmFL in the indicated conditions (n = 3). Bar graphs: mean ± SEM. Two-tailed Mann–Whitney U test. *, P < 
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ns, not significant.
Faliti et al. 
P2X7 in limiting pathogenic Tfh cell generation
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20171976
14
and embedded in paraffin wax. Sections of 3–5-µm thickness 
were prepared, mounted on glass slides, deparaffinized in xy-
lene, and rehydrated through graded alcohols, before staining 
with H&E or periodic-acid-Schiff reagent. Slides were evaluated 
in a blinded fashion by a board-certified veterinary pathologist 
(G. Pellegrini). Glomerular injury was assessed by light micros-
copy on 50 consecutive glomeruli/mouse using a histopatholog-
ical scoring system modified from Wang et al. (1999). Briefly, a 
grade of 0 indicated normal glomerular histology; scores 1 to 3 in-
dicated progressive severe glomerular injury, i.e., score 1: mildly 
thickened and hypereosinophilic mesangium, multiple clusters 
of nuclei, mild reduction in the number of glomerular capillar-
ies; score 2: moderately thickened and hypereosinophilic mesan-
gium, moderate diffuse hypercellularity, marked reduction in 
the number of glomerular capillaries, occasional inflammatory 
cells, mostly neutrophils; and score 3: noticeable enlargement 
of the glomerular tuft, abnormal glomerular shape (irregular 
rather than round), severely thickened and hypereosinophilic 
mesangium, occasional adhesions of the glomerular tuft to the 
Bowman’s capsule (synechiae), severe diffuse hypercellularity, 
loss of capillaries, occasional inflammatory cells, mostly neu-
trophils. To detect glomerular immune complexes by immuno-
fluorescence, kidneys were removed and immediately frozen in 
OCT (Tissue-Tek). Cryostat sections (4 µm) were stained with 
the following antibodies: AF488 goat anti–mouse IgG (highly 
cross-adsorbed; Southern Biotech), rat anti-mouse C3 (RmC11H9) 
Figure 9. Frequency of cTfh cells and P2X7 activity in healthy subjects and SLE and PAPS patients. (A) Representative dot plots for CXCR5+ cells and 
CCR7lo/−PD-1hi cells within cTfh cells of the indicated subjects and frequency of CCR7lo/−PD-1hi cells within cTfh cells in healthy (HD), SLE, and PAPS subjects. 
Two-tailed Mann–Whitney U test. (B) Serum CXCL13 concentration in HDs, SLE, and PAPS subjects. Two-tailed Mann–Whitney U test. (C) Representative time 
monitoring of YO-PRO-1 uptake in CD14−CD4+CD45RA−CXCR5+CCR7lo/−PD-1hi cTfh cells from PBMCs of the indicated subjects after stimulation with BzATP. 
Statistics of YO-PRO-1–permeable cells (two-tailed Mann–Whitney U test) and YO-PRO-1 uptake expressed as fold increase of mean fluorescence intensity at 
250 and 450 s (two-way ANO VA multiple comparisons, with Bonferroni’s correction) are shown. (D) Correlation of fold increase in YO-PRO-1 uptake at 450 s 
and percentage of cTfh cells. The correlation coefficient r and the respective P value were calculated with nonparametric Spearman test. (E) PCA of HDs and 
SLE and PAPS patients according to % cTfh cells, % YO-PRO-1+ cTfh cells, and YO-PRO-1 uptake at 450 s. Areas of spreading are highlighted to better visualize 
segregation of groups of subjects. Each dot in graphs represents a subject, and horizontal lines represent median values. *, P < 0.05; ***, P < 0.001; ****, P < 
0.0001. ns, not significant.
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followed by AF647 labeled goat anti–rat IgG (cross-adsorbed 
against mouse IgG; Southern Biotech). To detect renal infiltrat-
ing CD4 T lymphocytes, the following antibodies were applied to 
the sections: rat anti-mouse CD4 (clone: GK1.5; BD PharMingen) 
followed by AF488 goat anti–rat IgG (Invitrogen), hamster an-
ti-mouse ICOS (clone: C398.4A; eBioscience) followed by AF594 
goat anti–hamster IgG (Invitrogen). Slides were mounted with 
Gelvatol Mounting Media and stained with DAPI for the detection 
of nuclei. Images were acquired using a Leica TCS SP5 confocal 
microscope, with a HCX PL APO 40×/1.25 N.A. oil-immersion ob-
jective. Quantification was performed with ImageJ open-source 
software (National Institutes of Health; Schindelin et al., 2012). 
Regions of interest containing the glomeruli were manually de-
fined, and the background was excluded by applying a threshold 
on the intensity; the area above the threshold in these regions of 
interest was measured in three different fields of view for each 
sample and is expressed as percentage of the total glomerulus 
area. For histological analysis of GCs, spleens were frozen in 
OCT. Cryostat sections (4 µm) were stained with the following 
antibodies: AF594 anti–mouse IgD (clone: 11-26c.2a; BioLegend), 
Figure 10. P2RX7 expression and function in HDs and SLE and PAPS patients. (A) P2RX7 transcript quantification in CD4 naive and cTfh cells at different 
times after in vitro stimulation with anti-CD3/28 antibodies and upon shifting cells in IL-2 after 48-h stimulation. Data are from cells sorted from three different 
HDs. Unpaired Student’s t test. (B) P2RX7 transcripts in sorted CXCR5+ CD4 T cells from healthy (HD), SLE, and PAPS donors (n = 10). Two-tailed Mann–Whitney 
U test. A.U., arbitrary units. (C) Representative histograms of CellTrace Violet (CTV) dilution in purified CXCR5+CD4+ cells from the indicated subjects after 7-d 
culture in the presence of IL-7 and IL-15 either without or with BzATP. Percentages of proliferating cells within the marker are indicated. Statistics for prolifer-
ation and inhibition of proliferation by BzATP. Each dot represents a subject, and horizontal lines represent median values. Two-tailed Mann–Whitney U test. 
(D) Percentage inhibition of proliferation by BzATP in sorted CCR7lo/−PD-1hi Tfh cells from HDs and SLE individual subjects at day 7 of stimulation with IL-7 and 
IL-15. Number of tested donors is indicated in the graphs. Each dot represents a subject, and horizontal lines represent median values. Two-tailed Mann–Whit-
ney U test. (E) Representative contour plots for in vitro differentiation of naive CD4 cells from HDs and SLE donors (n = 4) into Tfh cells in the presence of the 
indicated stimuli and statistics (Student’s t test). Bar graphs: mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. ns, not significant.
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AF647 anti-mouse GL-7 (clone: GL-7; BioLegend), BV405 an-
ti-mouse CD4 (clone: GK1.5; BioLegend), unconjugated goat an-
ti-mouse PD-1 Ig (Novusbio) followed by AF488 rabbit anti–goat 
Ig (Invitrogen). Images were collected on a laser-scanning confo-
cal microscope with a HCX PL APO 40×/1.25 N.A. oil-immersion 
objective. GC area was measured using ImageJ (Schindelin et al., 
2012). To score GC frequency, total GC numbers were quantitated 
in three separate 10× fields of view of 2.4 mm2 (1,550 µm × 1,550 
µm) per spleen section.
Preparation of single-cell suspension from kidney
Kidneys were removed, minced, and digested with Liberase (0.14 
mg/ml; Roche) and DNase I (0.03 mg/ml; Sigma-Aldrich) in HBSS 
medium, for 30–40 min at 37°C. Tissue pieces were then pressed 
through a 70-µm strainer to obtain single-cell suspensions. Cells 
were enriched in leukocytes using an 80/20 Percoll gradient and 
centrifuged at 800 g for 20 min at room temperature. Lymphoid 
fractions were collected at the interphase of the Percoll gradient 
and used for flow cytometry.
Mouse cell isolation and flow cytometry
Single-cell suspensions were prepared by passing spleens 
through a 70-µm nylon mesh. After centrifugation at 1,500 rpm 
for 5 min, red blood cells were lysed in ACK-lysis buffer for 7 min. 
Lysis buffer was neutralized by washing once in staining buffer. 
Cells were stained with the following monoclonal antibodies: 
biotin-conjugated anti-CXCR5 (clone: 2G8; BD), PE-labeled anti 
ICOS (clone: 7E.17G9; BD) or PerCPCy5-labeled anti-ICOS (clone: 
C398.4A; BioLegend), APC-labeled anti PD-1 (clone: RMPI-30; 
BioLegend), Percp-eFluor710–labeled anti-CD3 (Clone: 17A2; 
eBioscience), AF488-labeled TCRβ (clone: H57-597; BioLegend), 
APC-Cy7–labeled anti-CD4 (clone: RM4-5; BioLegend), BV421 
anti-CD162 (PSGL1; clone 2PH1; BD), PeCy7-labeled anti-CD25 
(clone: PC61; BioLegend), PE-labeled anti-CD44 (clone: IM7; 
BioLegend), APC-labeled CD62L (clone: MEL-14; eBioscience), 
and BV421-labeled anti-CD197 (CCR7; clone: 4B12; BioLegend), 
APC-Cy7–labeled anti-CD19 (clone: 6D5; BioLegend), BV405-la-
beled B220 (clone: RA3-6B2; BioLegend), PE-labeled anti-Fas 
(clone: Jo2; BD), fluorescein-labeled peanut agglutinin (PNA; FL-
10-71; Vectorlabs), biotinylated anti-CD275 (ICO SL; clone: HK5.3; 
BioLegend), PE-labeled anti-CD138 (clone: 281-2; BD), APC-la-
beled anti-CD11c (clone: N418; eBioscience), APC-eFluor780–
labeled CD45.2 (clone: 104; eBioscience), and APC-Cy7–labeled 
anti-CD90.2 (clone: 30-H12; BioLegend). APC-labeled streptavi-
din was purchased from BioLegend and efluo405-labeled strepta-
vidin from eBioscience. Intracellular staining was performed 
using the BD Cytofix/Cytoperm and Perm/Wash buffers or, for 
intracellular FoxP3 (FITC-labeled, clone: FJK-16s; eBioscience) 
staining, the eBioscience FoxP3 staining buffer set. For intra-
cellular staining of IL-21 (R&D Systems), IFN-γ (PeCy7-labeled, 
clone: XMG1.2; eBioscience), and IL-17A (PerCP-Cy5–labeled, 
clone: eBio17B7; eBioscience), 5 × 106 splenocytes were cultured 
for 5 h at 37°C in 24-well plates in 2 ml culture medium contain-
ing ionomycin (750 ng/ml) and PMA (20 ng/ml). For the last 
4 h, Monensin (1,000× solution; eBioscience) was added to the 
cultures. IL-21 was detected with a recombinant mouse IL-21R 
subunit/human IgG1 Fc chimera (R&D Systems) with goat an-
ti-human Fcγ conjugated to AF488 (Jackson ImmunoResearch). 
For detection of activated caspases, Tfh cells were incubated with 
FITC-VAD-FMK (CaspGlow Fluorescein Active Caspase Staining 
Kit; BioVision) for 30–45 min at 37°C in RPMI-1640 according to 
the manufacturer sʼ protocol. Cells were then washed and resus-
pended in PBS for analysis by flow cytometry. Samples were ac-
quired on an LSRFortessa (BD Biosciences) flow cytometer. Data 
were analyzed using FlowJo software (TreeStar).
Tetramer staining
Tetramers were provided by the National Institutes of Health Te-
tramer Core Facility. Cells were stained for 2 h at 37°C with the 
following APC-labeled tetramers: I-Ab chicken OVA329–337 AAH 
AEI NEA, I-Ab chicken OVA328–337 HAA HAE INEA, I-Ab chicken 
OVA259–277 IIN FEK LTE WTS SNV MEER, and I-Ab human CLIP87–101 
PVS KMR MAT PLL MQA. All OVA tetramers gave comparable re-
sults in flow cytometry.
ELI SA and ELI SPOT assays
For total Ig isotype determination, ELI SA plates (Corning 96-
Well Half Area Flat Bottom Polystyrene High Bind) were coated 
for 3  h at room temperature with purified goat anti–mouse 
IgG, IgM, and IgA antibodies (Southern Biotech) used at a con-
centration of 10 µg/ml. After four washes with PBS 0.025% 
Tween-20 and blocking with PBS 1% BSA for 1 h at room tem-
perature, samples and standards (relative unlabeled mouse 
Ig; Southern Biotech) were diluted and incubated at room 
temperature for 4  h. Specific secondary goat anti–mouse Ig 
conjugated with alkaline-phosphatase were added after four 
washes with PBS and 0.025% Tween-20 and incubated for 2 h 
at room temperature. Plates were washed again, and the assay 
was developed with Sigma 104 phosphatase substrate. Plates 
were read at 405 nm. IgG-secreting cells were detected using 
ELI SPOT assay: 96-well plates (Millipore, MSI PS4510 Sterile, hy-
drophobic high protein binding Immobilon-P membrane) were 
coated with 10 µg/ml purified goat anti–mouse IgG (Southern 
Biotech) for 2 h at room temperature. After three washes with 
PBS solution, plates were blocked with PBS and 1% BSA and 
incubated for 30 min at 37°C. Serial dilutions of splenocytes 
were added in a final volume of 200 µl B cell medium (RPMI, 
10% Hyclone serum) and left at 37°C for 16  h. Subsequently, 
plates were washed three times with PBS and 0.25% Tween-20 
and four times with PBS and incubated for 2  h at room tem-
perature with biotinylated goat anti–mouse IgG (Southern Bio-
tech). After washing, avidin-peroxidase (HRP; Sigma-Aldrich) 
was added and left for 1 h at room temperature. The assay was 
developed with AEC (Sigma-Aldrich). For quantification of 
IgG-secreting cells, plates were acquired, counted, and quality 
controlled using an ELI SPOT reader and ImmunoSpot 5.1 soft-
ware (CTL Europe). For ANA detection, both indirect immuno-
fluorescence assay ANA-Hep-2 fixed cells (ORG 870; Orgentec) 
and microwell ELI SA plates coated with highly purified indi-
vidual antigens plus extracts from Hep-2 nuclei and nucleoli 
(QUA NTA Lite; Inova Diagnostics) were used. Briefly, fixed Hep-2 
cells were incubated with mouse sera (diluted 1:100), and ANAs 
were detected with AF488-labeled goat anti–mouse IgG (South-
ern Biotech). Slides were stained with DAPI and captured with a 
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Nikon Eclipse E800 upright microscope, with a 20×/0.75 N.A. ob-
jective. Images were analyzed with ImageJ open-source software 
for pattern recognition (Schindelin et al., 2012). The kit ELI SA 
(QUA NTA Lite) for the semiquantitative detection of ANAs in 
human serum was used and adapted for the detection of mouse 
ANAs. The antigens include chromatin (double-stranded DNA 
[dsDNA] and histones), Sm/RNP, SS-A, SS-B, Scl-70, centromere, 
PCNA, Jo-1, mitochondria (M-2), and ribosomal-P protein, as 
well as the extracts. Sera were diluted at 1:200 in ANA sample 
diluent and detected with HRP-conjugated goat anti–mouse IgG 
(Southern Biotech). Plates were read for the absorbance at 450 
nm within 1 h after addition of the stop solution.
Western blot
Tfh cells were isolated from mesenteric lymph nodes and PPs, 
washed with ice-cold PBS, and lysed with RIPA buffer 1× (Sigma) 
supplemented with protease inhibitor cocktail (Roche). Samples 
were centrifuged at 14,000 rpm for 10 min at 4°C and snap fro-
zen. Cleared protein lysate was denatured with loading buffer 
supplemented with 0.1  µM DTT for 10 min at 65°C. Samples 
were run on precast 4–12% bis-Tris protein gels (Bio-Rad) and 
then transferred onto polyvinylidene difluoride membranes 
using Trans-Blot Turbo Transfer System (Bio-Rad). Membranes 
were blocked with 10% (wt/vol) nonfat dry milk (Bio-Rad) and 
0.1% Tween-20 in TBS and incubated with appropriate antibod-
ies in TBS with 0.1% Tween-20 for 16 h at 4°C. The following 
antibodies were used: anti-GSD MDC1 (clone: A-7, sc-393656; 
Santa Cruz Biotechnology) and anti-actin (A2066; Sigma). 
Bound antibodies were revealed by incubation with secondary 
HRP-conjugated anti-mouse (7076, Cell Signaling Technology) 
or anti-rabbit (7074; Cell Signaling Technology) IgG antibodies 
in TBS with 0.1% Tween-20. Membranes were developed using 
the Pierce ECL Western blotting substrate (32209; Thermo Sci-
entific), signals were detected with the ImageQuant LAS 4000 
system in the standard acquisition mode (GE Healthcare Life 
Sciences), and bands were quantified using the Multi Gauge 
Analysis tool (Fujifilm).
Human samples and patients
Peripheral blood samples from patients with SLE and PAPS were 
obtained after informed consent was provided (local ethics com-
mittee approval no. 192_2016bis) during regular follow-up visits 
at the Lupus Clinic, IAS ST-Istituto Gaetano Pini, University of 
Milan, Italy. Inclusion criteria were age >18 yr, fulfillment of the 
American College of Rheumatology 1997 classification criteria 
for SLE (Hochberg, 1997) and 2006 classification criteria for an-
tiphospholipid syndrome (APS; Miyakis et al., 2006; Table S1). 
Exclusion criteria were treatment with B cell–depleting agents 
or experimental drugs. Disease activity was determined with 
SLE disease activity index (SLE DAI-2K; Gladman et al., 2002); 
clinical and laboratory data were obtained during the routine 
follow-up. Patients were characterized for antiphospholipid an-
tibodies (Lupus Anticoagulant, anticardiolipin IgG and IgM, and 
anti-β2GPI IgG and IgM; Andreoli et al., 2015) as well as ANA, 
anti-ENA, and anti-dsDNA antibodies (Ingegnoli et al., 2014). 
All experiments performed on human blood samples from HDs 
were approved by the ethics committee of Fondazione IRC CS Ca’ 
Granda Ospedale Maggiore Policlinico, and informed consent 
was obtained from all subjects.
Human cell isolation, stimulation, and flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated from 
blood by density-gradient centrifugation using Ficoll-Paque Plus 
gradient (GE Healthcare). CD4+ T cells were enriched by posi-
tive selection using human CD4 MicroBeads (Miltenyi Biotec), 
and then CD4+ T cell subsets were sorted to 99% purity with a 
FAC SAria (BD). For in vitro TCR stimulation, CD4+ naive and 
CXCR5+ cells were stimulated with anti-CD3 (5 µg/ml) and an-
ti-CD28 (1 µg/ml) mAbs. PBMCs were stained with the following 
antibodies: PE-Texas Red–labeled anti-CD4 (clone: MHCD0417; 
Life Technologies), QD655-labeled anti-CD45RA (clone: MEM-
56; Life Technologies), PE-labeled anti-CCR7 (clone: G043H7; 
BioLegend), purified mouse monoclonal IgG2b anti-CXCR5 (BRL-1, 
clone: 51505; R&D Systems) revealed by FITC-labeled anti–mouse 
IgG2b (Southern Biotech), PE-cyanine 5 (PeCy5)–labeled an-
ti-CD183 (CXCR3; clone: 1C6/CXCR3; BD), PE-labeled anti-CD196 
(CCR6; clone: 11A9; BD), BV785-labeled anti-CD279 (PD-1; clone: 
EH12.2H7; BioLegend). PeCy5-labeled anti-CD56 (clone: A07789; 
Beckman Coulter), anti-CD14 (clone: A07765; Beckman Coulter), 
anti-CD19 (clone: HIB19; BioLegend), anti-CD25 (clone: BC96; 
BioLegend), and anti-CD8 (clone: HIT8a; BioLegend) were in-
cluded as a dump channel to exclude contaminant cells.
Time monitoring of YO-PRO-1 uptake
106 human PBMCs were stained with the appropriate antibod-
ies, washed, resuspended in RPMI 1640 complete medium, 
and loaded with YO-PRO-1 iodide (Life Technologies) at a final 
concentration of 5  µM. The YO-PRO-1 uptake following cell 
stimulation with 1 mM BzATP (Sigma) was monitored on an LSR-
Fortessa for 480 s, and the kinetics was analyzed using FlowJo 
software (TreeStar). Murine splenocytes (106) were stimulated 
with 0.1 mM BzATP.
In vitro cytokine-driven proliferation assay
For cytokine-driven proliferation assay, sorted CXCR5+ or 
CCR7lo/−PD-1hi CD4 T cells were labeled with 5  µM Cell Trace 
Violet (Life Technologies) in PBS for 20 min at 37°C; staining 
was blocked by adding an equal volume of filtered prewarmed 
FBS. Cells were centrifuged at 1,500 rpm for 5 min and plated at 
a minimal density of 25,000 cells/well in RMPI 1640 complete 
medium. Plated cells were stimulated with recombinant IL-7 and 
IL-15 (R&D Systems) at 25 ng/ml, with BzATP at a final concen-
tration of 100 µM when indicated. Cell proliferation and viability 
were assessed after 7 d using LSRFortessa.
In vitro CD4 cell differentiation to Tfh cell
CD4+ cells were enriched from PBMCs by positive selection 
with anti-CD4 MicroBeads (Miltenyi Biotec). Naive T cells were 
sorted on a FAC SAria (BD) to 99% purity as CD8−CD25−CD14−
CD19−CD4+CD45RA+CCR7+ cells, activated by Dynabeads Human 
T-Activator CD3/CD28 (Life Technologies), and cultured with 
recombinant activin A (100 ng/ml), human IL-12 (5 ng/ml), IL-7 
(4 ng/ml; all from R&D Systems), and BzATP where indicated, 
in AIM-V medium (Life Technologies), as described (Locci et al., 
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2016). After 5 d, cells were stained with Zombie Aqua dye (Bio-
Legend) to exclude dead cells, anti-human CXCR5, and PD-1 an-
tibodies and analyzed on an LSRFortessa.
Real-time quantitative PCR
CXCR5+ CD4 cells were sorted on a FAC SAria (BD) from PBMCs. 
RNA was extracted using the RNeasy Mini Kit (Qiagen) and con-
verted to cDNA. Random primers and Moloney murine leukemia 
virus reverse transcription (Invitrogen) were used for cDNA syn-
thesis. Transcripts were quantified by real-time quantitative PCR 
on an ABI PRI SM 7900HT with Applied Biosystem predesigned 
TaqMan gene expression assays and reagents according to the 
manufacturer’s instructions. The following probe was used (iden-
tified by Applied Biosystem assay identification number): P2RX7 
(Hs00175721_m1). For each sample, mRNA abundance was nor-
malized to the amount of TAT-box binding protein (Hs00427620_
m1), used as gene reference, and expressed as arbitrary units.
Meta-analysis of gene expression data in CD4 cells
All data were measured on Affymetrix arrays and have been 
downloaded from the Gene Expression Omnibus (GEO). The fol-
lowing series of GEO data were used: GSE46892 (Huang et al., 
2014), GSE49314 (Weber et al., 2015), GSE56883 (Moriyama et al., 
2014), GSE21381 (Yusuf et al., 2010), and GSE24574 (Kitano et al., 
2011). Microarray probe fluorescence signals were converted to 
log2 expression values using the Robust Multiarray Average pro-
cedure (Irizarry et al., 2003) of the affy Bioconductor package. 
Fluorescence intensities were background-adjusted and normal-
ized using quantile normalization, and expression values were 
calculated using median polish summarization and custom chip 
definition files for a total of 18,139 custom probe sets for Mouse 
Genome 430 2.0 Array based on Entrez genes (Mouse4302_Mm_
ENT REZG version 21.0.0). All data analyses were performed in R 
version 3.3.3 using Bioconductor libraries and R statistical pack-
ages. The expression change of any caspase was quantified as the 
difference between its log2 expression level in any sample of Tfh 
cells and its average log2 gene expression signal in naive CD4 cells 
(log2 fold-change).
PCA
PCA was performed using the “prcomp{stats}” method in R and 
visualized with ggplot2 library. Datasets were pruned for miss-
ing values before analysis; thus a total of 77 samples were used 
for PCA (28 HD, 14 PAPS, and 35 SLE). The percent contributions 
of each variable to the segregation process were determined as 
cumulative sum of absolute values of the PCA loadings, which are 
an estimate of how much each variable used in the PCA analysis 
contribute to each of the new variables (the principal compo-
nents) after the PCA transformation.
Statistical analysis
Statistical analysis was performed with Prism software (Graph-
Pad). Results were analyzed using the nonparametric Mann–
Whitney test, Student’s unpaired t test, and two-way ANO VA 
with Bonferroni posttest analysis, as indicated. Results are pre-
sented as mean ± SEM. Values of P were indicated throughout as 
*, P < 0.05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001.
Online supplemental material
Fig. S1 shows the phenotypic analysis of B cells, the distribution 
of CD4+ T cells for CD44 and CD62L, and frequencies of T reg and 
Tfr cells in untreated and pristane-treated WT and P2rx7−/− mice. 
Fig. S2 shows the increase of ICOS+ CD4 T cells in kidneys of pris-
tane-treated P2rx7−/− mice. Fig. S3 shows gasdermin and caspase 
expression in CD4 and Tfh cells. Fig. S4 shows the distribution 
of functional cTfh cell subsets and the ratio of (cTfh17 + cTfh2) 
with cTfh1 cells in HDs,SLE, and PAPS patients, and YO-PRO-1 
uptake inhibition in cTfh cells by A438079. Table S1 lists the de-
mographic, clinical, and laboratory characteristics of SLE and 
PAPS patients and HDs.
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Figure S1. Phenotypic analysis of B cells, T effector cells, and T reg cells in WT and P2rx7−/− mice. (A) Representative contour plots of B2 B cells in the 
spleen of WT and P2rx7−/− mice. Frequencies and absolute numbers from untreated WT (n = 6) and P2rx7−/− (n = 6) mice and treated WT (n = 15) and P2rx7−/− 
(n = 14) mice of marginal zone (Mz) and follicular (Fol) B cells gated as CD21+CD23− and CD21loCD23+ cells (as depicted in contour plots), respectively, among 
CD19+B220+ total B cells. (B) CD44 and CD62L staining of TCRβ+CD4+ cells. Numbers indicate percentages of CD44+CD62L− (effector) and CD44−CD62L+ 
(naive) cells within displayed quadrants; untreated WT (n = 10), P2rx7−/− (n = 8), treated WT (n = 29), and P2rx7−/− (n = 29) mice. (C) Representative contour 
plots for CD25 and Foxp3 on gated CD4+ T cells and frequency of conventional T reg cells in the spleen of the indicated mice. Untreated WT (n = 6) and 
P2rx7−/− (n = 5) mice; treated WT (n = 12) and P2rx7−/− (n = 13) mice. (D) Representative contour plots used to define Tfh and Tfr cells on gated CXCR5+ICOS+ 
CD4+ T cells. Bar graphs (mean ± SEM) represent ratios of GC B/Tfr (left) and Tfh/Tfr (right) cells in the spleen of the same mice as above. Each dot in the 
graphs represents an individual mouse (mean ± SEM is shown). Two-tailed Mann–Whitney U test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
ns, not significant.
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Figure S2. Increase of ICOS+ CD4 T cells in kidneys in pristane-treated P2rx7−/− mice. (A) Gating strategy for quantifying kidney-infiltrating CD44+ICOS+ 
effector CD4 T cells, and frequency of CD4+ and CD44+ICOS+ T cells from at least five animals. FSC, forward scatter; SSC, side scatter. Mean ± SEM, two-
tailed Mann–Whitney U test. (B) Representative confocal immunofluorescence images of fixed kidney cryosection stained with anti-CD4 (green), anti-ICOS 
(red) antibodies and DAPI (blue) showing ICOS+ T cells within glomeruli of WT and P2rx7−/− mice. Bars, 20 µm. *, P < 0.05; **, P < 0.01; ***, P < 0.001. ns, 
not significant.
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Figure S3. Gasdermins and caspases expression in naive CD4 and Tfh cells. (A) Heat map representing the log2 expression levels of genes encoding 
mouse gasdermins in CD4 naive and Tfh cells based on data derived from publicly available gene expression datasets (numbers on the left are accession 
codes). (B) Heat map showing fold changes of caspases in Tfh compared with naive CD4 cells (accession codes on top).
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Figure S4. Distribution of functional cTfh cell subsets in CXCR5+ cells from HDs and SLE and PAPS patients. P2X7-dependent YOP RO-1 uptake in 
cTfh cells. (A) Representative contour plots of CXCR5+ cTfh cells from healthy (HD), SLE, and PAPS subjects for CCR6 and CXCR3, and distribution of Tfh1, 
Tfh1/17, Tfh17, and Tfh2 cells in individual subjects from different groups (HD, n = 7; SLE, n = 8; and PAPS, n = 11; see Results for details). (B) Ratio between 
(Tfh17 + Tfh2) and Tfh1 cells in the same subjects. (C) Representative uptake of YO-PRO-1 in electronically gated CCR7loPD-1hi CXCR5+ T cells stimulated with 
BzATP (0.1 mM) or preincubated before stimulation with A438079 to allosterically block pore formation. Two-tailed Mann–Whitney U test. *, P < 0.05; **, P 
< 0.01; ***, P < 0.001. ns, not significant.
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Table S1. Demographic, clinical, and laboratory characteristics of SLE and PAPS patients and HDs
Characteristic SLE (n = 42) PAPS (n = 14) HD (n = 31)
Female/male, n 41/1 8/6 29/2
Median age, yr (range) 43 (26–76) 51 (39–68) 41 (25–62)
Median disease duration, yr (range) 17 (0.5–48) 13.65 (2–24) NA
 Onset <18 yr 12 (28) 0 (0) NA
Laboratory tests
ANA positivity 40 (95) 6 (42.8) NA
Anti-ENA positivity 19 (45) 0 (0) NA
 Anti-SSA/Ro 13 (30.9) NA NA
 Anti-Sm 6 (14.3) NA NA
 Anti-RNP 6 (14.3) NA NA
Anti-dsDNA positivitya 22 (52.4) 1 (7.14) NA
 Low titer 7 (16.7) 1 (7.14) NA
 Medium/high titer 15 (36) 0 (0) NA
LA 12 (28.5) 13 (93) NA
Anti-β2GPI IgGb 5 (11.9) 12 (85.7) NA
Anti-β2GPI IgMb 2 (4.7) 5 (35.7) NA
Anti-CL IgGb 7 (16.6) 13 (92.8) NA
Anti-CL IgMb 2 (4.7) 2 (14.3) NA
Low C3c 19 (45.2) 4 (28.6) NA
Low C4c 27 (64.3) 7 (50) NA
Hypergammaglobulinemiad 14 (33) 3 (21) NA
Clinical manifestations (ever)
SLE DAI-2K, median (IQR) 4 (2–6) NA NA
Skin rash 9 (21.4) NA NA
Alopecia 2 (4.76) NA NA
Hematologic involvemente 12 (28.6) NA NA
Arthritis 11 (26) NA NA
Myositis 1 (2.4) NA NA
Glomerulonephritis 2 (4.76) NA NA
Thrombotic APS 6 (14) 11 (78.6) NA
Obstetric APS 0 (0) 14 (28.6) NA
Therapy
Equivalent prednisone dose
 Median cumulative dose, mg (IQR) 36.5 (15–58.4) NA NA
 Median daily dose, mg/die (IQR) 5 (2.5–10) NA NA
Ongoing DMA RDs
 Hydroxychloroquine 28 (66.7) 9 (64) NA
 Mycophenolate mofetil 8 (19) 1 (7) NA
 Azathioprine 5 (11.9) 0 (0) NA
 Methotrexate 3 (7) 0 (0) NA
 Cyclosporine 5 (11.9) 0 (0) NA
Data are n (%) unless noted otherwise. Anti-CL, anti-cardiolipin; anti-ENA, anti–extractable antinuclear antigens; IQR, interquartile range; DMA RD, 
disease-modifying antirheumatic drug; GPL/MPL, IgG/IgM antiphospholipid units; LA, lupus anticoagulant; NA, not applicable.
aAnti-dsDNA has been detected as previously reported (Ingegnoli et al., 2014); anti-dsDNA titers were defined as low if <40 UI/ml, medium/high if >40 UI/
ml.
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bAnti-β2GPI and anti-CL positivity was defined as medium/high titer according to 2006 revised classification criteria for APS (>99th percentile for anti-
β2GPI and >40 GPL/MPL for anti-CL; Miyakis et al., 2006).
cLow C3 was defined as <80 mg/dL; low C4 as <15 mg/dL.
dHypergammaglobulinemia: >20% of total serum proteins.
eHematologic involvement: leukopenia, thrombocytopenia based on SLE DAI-2K definitions (Gladman et al., 2002) and Coombs-positive hemolytic anemia.
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